[A real-world study of first-line albumin-bound paclitaxel in the treatment of advanced pancreatic cancer in China].

<b>Objective:</b> To observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel as first-line treatment for patients with advanced pancreatic cancer in China, and to explore the prognosis-related molecules in pancreatic cancer based on next-generation sequencing (NGS) of tumor tissues. <b>Methods:</b> From December 2018 to December 2020, patients with locally advanced or metastatic pancreatic cancer were recruited to accept albumin-bound paclitaxel as first-line treatment in the oncology departments of 24 hospitals in East China. The primary endpoints were overall survival (OS) and treatment related adverse events, and the secondary endpoint was progression-free survival (PFS). Adverse effects were graded using Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0). NGS sequencing on the primary or metastatic tissue samples of pancreatic cancer obtained through surgical resection or biopsy was performed. <b>Results:</b> This study recruited 229 patients, including 70 patients with locally advanced pancreatic cancer (LAPC) and 159 patients with metastatic pancreatic cancer (mPC). The disease control rate was 79.9% and the objective response rate is 36.3%.The common adverse effects during treatment were anaemia (159 cases), leucopenia (170 cases), neutropenia (169 cases), increased aminotransferases (110 cases), and thrombocytopenia (95 cases), and the incidence of grade 3-4 neutropenia is 12.2% (28/229). The median follow-up time was 21.2 months (95% <i>CI</i>: 18.5-23.1 months). The median PFS (mPFS) was 5.3 months (95% <i>CI</i>: 4.37-4.07 months) and the median OS (mOS) was 11.2 months (95% <i>CI</i>: 9.5-12.9 months). The mPFS of patients with LAPC was 7.4 months (95% <i>CI</i>: 6.6-11.2 months), and their mOS was 15.5 months (95% <i>CI</i>: 12.6-NA months). The mPFS of patients with mPC was 3.9 months (95% <i>CI</i>: 3.4-5.1 months), and their mOS was 9.3 months (95% <i>CI</i>: 8.0-10.8 months). Multivariate Cox regression analysis showed that clinical stage (<i>HR</i>=1.47, 95% <i>CI</i>: 1.06-2.04), primary tumor site (<i>HR</i>=0.64, 95% <i>CI</i>: 0.48-0.86), Eastern Cooperative Oncology Group Performance Status (ECOG PS) score (<i>HR</i>=2.66, 95% <i>CI</i>: 1.53-4.65), and whether to combine radiotherapy (<i>HR</i>=0.65, 95% <i>CI</i>: 0.42-1.00) were independent influencing factors for the PFS of these patients. The primary tumor site (<i>HR</i>=0.68, 95% <i>CI</i>: 0.48-0.95), ECOG score (<i>HR</i>=5.82, 95% <i>CI</i>: 3.14-10.82), and whether to combine radiotherapy (<i>HR</i>=0.58, 95% <i>CI</i>: 0.35-0.96) were independent influencing factors of the OS of these patients. The most frequent gene mutations in these advanced stage pancreatic patients were <i>KRAS</i> (89.66%), <i>TP53</i> (77.01%), <i>CDKN2A</i> (32.18%), and <i>SMAD4</i> (21.84%) by NGS of tumor tissues from 87 pancreatic cancer patients with sufficient specimens. Further analysis revealed that mutations in <i>CDKN2B</i>, <i>PTEN</i>, <i>FGF6</i>, and <i>RBBP8</i> genes were significantly associated with an increased risk of death (<i>P</i>＜0.05). <b>Conclusion:</b> Albumin-bound paclitaxel as first-line treatment demonstrated feasible anti-tumor efficacy and manageable safety for patients with advanced pancreatic cancer in China.